P230026/S003: Lacrosse NSE ALPHA Coronary Dilatation Catheter
FDA’s recorded scope: a cleanroom renovation (new equipment) and the relocation of a dust collector machine
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 3 FDA records to the applicant name NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.). 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 22, 2026 to Jul 22, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NWX appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P230026, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 5f Kdx Nagoya Sakae Bldg., 4-5-3, Sakae, Naka-Ku, Nagoya. Recorded on P230026/S003, decision dated Jul 22, 2026.
Catheter, percutaneous transluminal coronary angioplasty (ptca), cutting/scoring.
FDA’s recorded scope: a cleanroom renovation (new equipment) and the relocation of a dust collector machine
FDA’s recorded scope: adding equipment and manufacturing aids for device production
FDA’s recorded scope: endotoxin equipment and testing methodology changes
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.